ECM
IONS icon

ETrade Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

ETrade Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$269K Buy
5,680
+510
+10% +$28.3K 0.01% 745
2020
Q2 		$305K Sell
5,170
-951
-16% -$52.9K 0.01% 655
2020
Q1 		$289K Buy
6,121
+916
+18% +$51.1K 0.01% 600
2019
Q4 		$314K Buy
5,205
+244
+5% +$14.5K 0.01% 662
2019
Q3 		$297K Sell
4,961
-556
-10% -$36.2K 0.01% 678
2019
Q2 		$354K Buy
5,517
+824
+18% +$58.2K 0.01% 644
2019
Q1 		$381K Sell
4,693
-1,579
-25% -$102K 0.01% 615
2018
Q4 		$339K Sell
6,272
-824
-12% -$42K 0.01% 583
2018
Q3 		$366K Sell
7,096
-8
-0.1% -$376 0.01% 622
2018
Q2 		$296K Buy
7,104
+263
+4% +$11.7K 0.01% 654
2018
Q1 		$302K Sell
6,841
-79
-1% -$4.01K 0.01% 621
2017
Q4 		$348K Sell
6,920
-34
-0.5% -$1.86K 0.01% 587
2017
Q3 		$353K Buy
6,954
+321
+5% +$16.8K 0.01% 554
2017
Q2 		$337K Buy
6,633
+1,633
+33% +$76K 0.01% 536
2017
Q1 		$201K Buy
+5,000
New +$225K 0.01% 617

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

ETrade Capital Management's IONS Position: Q3 2020 in Review

ETrade Capital Management increased its Ionis Pharmaceuticals (IONS) stake by 9.9% in Q3 2020, buying an estimated $28.3K and bringing the position to 5,680 shares worth $269K. The position accounts for 0.01% of the portfolio, ranked #745.

ETrade Capital Management first reported a position in IONS in Q1 2017 and has held it in 15 quarters since. The position peaked at $381K in Q1 2019. 368 funds tracked by Wall St. Rank hold IONS as of Q3 2020.

  • ETrade Capital Management held 5,680 shares of Ionis Pharmaceuticals worth $269K as of Q3 2020.
  • ETrade Capital Management bought 510 Ionis Pharmaceuticals shares in Q3 2020, an estimated $28.3K.
  • Ionis Pharmaceuticals made up 0.01% of ETrade Capital Management's portfolio in Q3 2020, its #745 holding.
  • ETrade Capital Management first reported a position in Ionis Pharmaceuticals in Q1 2017 and has held it in 15 quarters since.
  • ETrade Capital Management's Ionis Pharmaceuticals position peaked at $381K in Q1 2019.
  • 368 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.